AEON Biopharma to Present at Lake Street’s BIG10 Conference
Event summary
- AEON Biopharma will host 1x1 investor meetings at Lake Street Capital Markets’ BIG10 Conference on September 10, 2026.
- The company is advancing ABP-450, a biosimilar to BOTOX®, for full-label U.S. market entry.
- ABP-450 is manufactured by Daewoong Pharmaceutical in an FDA-authorized facility.
- AEON holds exclusive rights for therapeutic indications of ABP-450 in key global markets.
The big picture
AEON Biopharma is positioning itself to disrupt the $3.0 billion U.S. therapeutic neurotoxin market with its biosimilar ABP-450. The company’s strategy hinges on leveraging Daewoong Pharmaceutical’s manufacturing capabilities and securing regulatory approvals to challenge established players like Evolus. Success in this space could redefine the competitive landscape for neurotoxin therapies.
What we're watching
- Regulatory Approval
- The pace at which AEON secures full-label approval for ABP-450 in the U.S. will determine its market entry timeline.
- Market Competition
- Whether AEON can differentiate ABP-450 from Evolus’ Jeuveau® in the therapeutic neurotoxin space.
- Investor Sentiment
- How investor meetings at the BIG10 Conference impact AEON’s valuation and access to capital.